Payment overview · 2025
General Payments
$391.40
20 reported records · 10 companies
Healthcare provider profile · identity verified
Jeffrey Scott Swenson, MD
Allopathic & Osteopathic Physicians|Family Medicine · RUPERT, ID · NPI 1376531004
Verified facts
What the public records show
CMS Open Payments records show Jeffrey Scott Swenson, MD received $391.40 in general payments during 2025 across 20 reported records.
ABBVIE INC. accounted for 31.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synthroid by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $122.62 | 31.3% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $45.85 | 11.7% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $39.92 | 10.2% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $34.96 | 8.9% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $34.17 | 8.7% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $33.35 | 8.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $28.13 | 7.2% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $23.67 | 6.0% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $14.53 | 3.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.20 | 3.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $391.40 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $93.43 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $65.57 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $45.85 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $39.92 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $34.96 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $34.17 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $33.35 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $29.19 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $28.13 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $28.13 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $23.67 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $23.67 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $23.67 | 1 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $23.67 | 1 | 2025 |
Source payment records
|
|||||
| ROTATEQ Normalized: rotateq |
Biological | Merck Sharp & Dohme LLC | $23.67 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $14.53 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.20 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.20 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 76 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 65 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
76 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
65 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Losartan Potassium | Losartan Potassium | 394 | 101 |
| Levothyroxine Sodium | Levothyroxine Sodium | 371 | 88 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 279 | 79 |
| Amlodipine Besylate | Amlodipine Besylate | 278 | 73 |
| Pantoprazole Sodium | Pantoprazole Sodium | 271 | 85 |
| Lisinopril | Lisinopril | 231 | 60 |
| Meloxicam | Meloxicam | 230 | 64 |
| Atorvastatin Calcium | Atorvastatin Calcium | 226 | 69 |
| Hydrochlorothiazide | Hydrochlorothiazide | 226 | 51 |
| Omeprazole | Omeprazole | 212 | 59 |
| Simvastatin | Simvastatin | 204 | 53 |
| Gabapentin | Gabapentin | 200 | 51 |
| Metformin Hcl | Metformin Hcl | 172 | 45 |
| Potassium Chloride | Potassium Chloride | 153 | 40 |
| Metformin Hcl Er | Metformin Hcl | 150 | 44 |
| Trazodone Hcl | Trazodone Hcl | 145 | 39 |
| Allopurinol | Allopurinol | 140 | 36 |
| Sertraline Hcl | Sertraline Hcl | 130 | 30 |
| Metoprolol Succinate | Metoprolol Succinate | 121 | 30 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 119 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 119 | 32 |
| Furosemide | Furosemide | 117 | 35 |
| Citalopram Hbr | Citalopram Hydrobromide | 85 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 85 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 82 | 42 |
| Mounjaro | Tirzepatide | 76 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 70 | 18 |
| Alendronate Sodium | Alendronate Sodium | 69 | 17 |
| Tramadol Hcl | Tramadol Hcl | 69 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 65 | 18 |
| Ozempic | Semaglutide | 65 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 62 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 58 | 15 |
| Carvedilol | Carvedilol | 56 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 56 | 15 |
| Estradiol | Estradiol | 55 | 15 |
| Glimepiride | Glimepiride | 54 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 53 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 53 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 52 | 11 |
| Dutasteride | Dutasteride | 50 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 48 | 22 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 46 | suppressed |
| Cephalexin | Cephalexin | 45 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 45 | 17 |
| Donepezil Hcl | Donepezil Hcl | 44 | suppressed |
| Famotidine | Famotidine | 42 | 13 |
| Pregabalin | Pregabalin | 42 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 41 | 32 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 40 | 33 |
| Glipizide Er | Glipizide | 40 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 39 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 39 | 11 |
| Lorazepam | Lorazepam | 39 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 38 | suppressed |
| Atenolol | Atenolol | 38 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 37 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 36 | suppressed |
| Topiramate | Topiramate | 36 | 14 |
| Trulicity | Dulaglutide | 35 | suppressed |
| Chlorthalidone | Chlorthalidone | 34 | suppressed |
| Prednisone | Prednisone | 34 | 21 |
| Ropinirole Hcl | Ropinirole Hcl | 34 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 33 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 32 | suppressed |
| Memantine Hcl | Memantine Hcl | 32 | suppressed |
| Primidone | Primidone | 32 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 31 | suppressed |
| Klor-Con M20 | Potassium Chloride | 31 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 27 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 23 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 30 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 30 | suppressed |
| Spironolactone | Spironolactone | 30 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 29 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 29 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | suppressed |
| Ezetimibe | Ezetimibe | 27 | suppressed |
| Ramipril | Ramipril | 27 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | 13 |
| Baclofen | Baclofen | 25 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 25 | suppressed |
| Finasteride | Finasteride | 25 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 17 |
| Venlafaxine Hcl | Venlafaxine Hcl | 23 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 22 | suppressed |
| Diazepam | Diazepam | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Alprazolam | Alprazolam | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Azithromycin | Azithromycin | 20 | 20 |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Calcitriol | Calcitriol | 19 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 14 |
| Divalproex Sodium | Divalproex Sodium | 18 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Olanzapine | Olanzapine | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 17 | suppressed |
| Levemir Flexpen | Insulin Detemir | 16 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 16 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 15 | suppressed |
| Eliquis | Apixaban | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | 13 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 13 | suppressed |
| Celecoxib | Celecoxib | 13 | suppressed |
| Febuxostat | Febuxostat | 13 | suppressed |
| Imiquimod | Imiquimod | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Cartia Xt | Diltiazem Hcl | 12 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Selegiline Hcl | Selegiline Hcl | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Cabergoline | Cabergoline | 11 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 11 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Risperdal Consta | Risperidone Microspheres | 11 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $391.40 · 20 records | ABBVIE INC. | CAPVAXIVE, Cologuard Collection Kit, ELIQUIS, ENFLONSIA, FARXIGA, GARDASIL 9, INSPIRE, JARDIANCE, LEQVIO, M-M-R II, MOUNJARO, Ozempic, QULIPTA, ROTATEQ, Rybelsus, UBRELVY, VRAYLAR, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error